IDiyas

For the Inventor, By the Inventor

The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Patent No.:

US 12213965 B1

PDFFull Text
Date of Patent:
Feb. 04, 2025

Filed:

Jul. 05, 2021

Riluzole prodrugs and their use

Applicant:

Biohaven Therapeutics Ltd., New Haven, CT (US);

Inventors:

Jay Edward Wrobel, Lawrenceville, NJ (US);

Allen B. Reitz, Lansdale, PA (US);

Jeffery Claude Pelletier, Lafayette Hill, PA (US);

Garry Robert Smith, Royersford, PA (US);

Haiyan Bian, Princeton, NJ (US);

Assignee:

Biohaven Therapeutics Ltd., Tortola, VG;

Attorney:
Primary Examiner:

Noble E Jarrell

Int. Cl.
CPC ...
A61K 31/428 (2006.01); A61K 9/00 (2006.01); A61K 9/16 (2006.01); A61K 9/20 (2006.01); A61K 31/454 (2006.01); A61K 31/496 (2006.01); A61K 31/506 (2006.01); A61K 31/5377 (2006.01); A61K 31/541 (2006.01); A61K 38/05 (2006.01); A61K 38/06 (2006.01); A61K 39/00 (2006.01); A61K 45/06 (2006.01); A61P 25/00 (2006.01); A61P 25/28 (2006.01); A61P 35/00 (2006.01); C07D 277/82 (2006.01); C07D 417/12 (2006.01); C07K 5/062 (2006.01); C07K 5/083 (2006.01); C07K 5/087 (2006.01); A61K 9/48 (2006.01);
U.S. Cl.
CPC ...
A61K 31/428 (2013.01); A61K 9/006 (2013.01); A61K 9/1617 (2013.01); A61K 9/2004 (2013.01); A61K 31/454 (2013.01); A61K 31/496 (2013.01); A61K 31/506 (2013.01); A61K 31/5377 (2013.01); A61K 31/541 (2013.01); A61K 38/05 (2013.01); A61K 38/06 (2013.01); A61K 39/4636 (2023.05); A61K 45/06 (2013.01); A61P 25/00 (2018.01); A61P 25/28 (2018.01); A61P 35/00 (2018.01); C07D 277/82 (2013.01); C07D 417/12 (2013.01); C07K 5/06026 (2013.01); C07K 5/0806 (2013.01); C07K 5/0808 (2013.01); C07K 5/0812 (2013.01); A61K 9/0056 (2013.01); A61K 9/2018 (2013.01); A61K 9/2063 (2013.01); A61K 9/485 (2013.01); A61K 9/4858 (2013.01); A61K 9/4866 (2013.01); A61K 2300/00 (2013.01);
Abstract

Pharmaceutical compositions of the invention include substituted riluzole prodrugs useful for the treatment of cancers including melanoma, breast cancer, brain cancer, and prostate cancer through the release of riluzole. Prodrugs of riluzole have enhanced stability to hepatic metabolism and are delivered into systemic circulation by oral administration, and then cleaved to release riluzole in the plasma via either an enzymatic or general biophysical release process.

Find Patent Forward Citations

Loading…